Singapore First In Asia To Offer Bayer’s Novel Radiation Therapy For Advanced Prostate Cancer With Bone Metastases
This article was originally published in PharmAsia News
Bayer has launched Xofigo (Ra 223) in Singapore, making it the first Asian nation to offer the treatment and cementing the wealthy city state’s claims as a cutting edge cancer treatment hub.
You may also be interested in...
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.